Mexico
· Delayed Price · Currency is MXN FibroGen Statistics
Total Valuation
FibroGen has a market cap or net worth of MXN 606.41 million. The enterprise value is 2.20 billion.
| Market Cap | 606.41M |
| Enterprise Value | 2.20B |
Important Dates
The last earnings date was Monday, May 5, 2025.
| Earnings Date | May 5, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
| Current Share Class | 101.04M |
| Shares Outstanding | n/a |
| Shares Change (YoY) | +2.82% |
| Shares Change (QoQ) | +0.31% |
| Owned by Insiders (%) | n/a |
| Owned by Institutions (%) | n/a |
| Float | 92.73M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 0.98 |
| PB Ratio | -0.16 |
| P/TBV Ratio | n/a |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | -2.22 |
| EV / Sales | 3.81 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | -0.76 |
Financial Position
The company has a current ratio of 1.47
| Current Ratio | 1.47 |
| Quick Ratio | 0.60 |
| Debt / Equity | n/a |
| Debt / EBITDA | n/a |
| Debt / FCF | -0.65 |
| Interest Coverage | -15.88 |
Financial Efficiency
| Return on Equity (ROE) | n/a |
| Return on Assets (ROA) | -25.66% |
| Return on Invested Capital (ROIC) | n/a |
| Return on Capital Employed (ROCE) | -161.25% |
| Revenue Per Employee | 2.74M |
| Profits Per Employee | -4.41M |
| Employee Count | 225 |
| Asset Turnover | 0.09 |
| Inventory Turnover | 10.95 |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -68.12% in the last 52 weeks. The beta is 0.88, so FibroGen's price volatility has been lower than the market average.
| Beta (5Y) | 0.88 |
| 52-Week Price Change | -68.12% |
| 50-Day Moving Average | 7.24 |
| 200-Day Moving Average | 8.83 |
| Relative Strength Index (RSI) | 48.94 |
| Average Volume (20 Days) | 1,118 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | 1.13 |
Income Statement
In the last 12 months, FibroGen had revenue of MXN 617.22 million and -991.42 million in losses. Loss per share was -9.91.
| Revenue | 617.22M |
| Gross Profit | -1.70B |
| Operating Income | -2.73B |
| Pretax Income | -3.20B |
| Net Income | -991.42M |
| EBITDA | -2.67B |
| EBIT | -2.73B |
| Loss Per Share | -9.91 |
Balance Sheet
The company has 1.05 billion in cash and 1.88 billion in debt, giving a net cash position of -827.08 million.
| Cash & Cash Equivalents | 1.05B |
| Total Debt | 1.88B |
| Net Cash | -827.08M |
| Net Cash Per Share | n/a |
| Equity (Book Value) | -3.83B |
| Book Value Per Share | -46.58 |
| Working Capital | 1.32B |
Cash Flow
In the last 12 months, operating cash flow was -2.88 billion and capital expenditures -5.54 million, giving a free cash flow of -2.88 billion.
| Operating Cash Flow | -2.88B |
| Capital Expenditures | -5.54M |
| Free Cash Flow | -2.88B |
| FCF Per Share | n/a |
Margins
Gross margin is -275.59%, with operating and profit margins of -442.13% and -160.63%.
| Gross Margin | -275.59% |
| Operating Margin | -442.13% |
| Pretax Margin | -517.76% |
| Profit Margin | -160.63% |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
FibroGen does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -2.82% |
| Shareholder Yield | -2.82% |
| Earnings Yield | -163.49% |
| FCF Yield | -475.11% |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
FibroGen has an Altman Z-Score of -13.71. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -13.71 |
| Piotroski F-Score | n/a |